Literature DB >> 33392698

Nutritional and pharmacological strategy in children with short bowel syndrome.

Michael E Höllwarth1, Valeria Solari2.   

Abstract

Short bowel syndrome in neonates is a severe and life-threatening disease after a major loss of small bowel with or without large bowel. Intestinal adaptation, by which the organism tries to restore digestive and absorptive capacities, is entirely dependent on stimulation of the active enterocytes by enteral nutrition. This review summarizes recent knowledge about the pathophysiologic consequences after the loss of different intestinal parts and outlines the options for enteral nutrition and pharmacological therapies to support the adaptation process.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33392698     DOI: 10.1007/s00383-020-04781-2

Source DB:  PubMed          Journal:  Pediatr Surg Int        ISSN: 0179-0358            Impact factor:   1.827


  93 in total

1.  Pediatric Short Bowel Syndrome: Predicting Four-Year Outcome after Massive Neonatal Resection.

Authors:  Teresa Capriati; Daniela Giorgio; Fabio Fusaro; Manila Candusso; Paolo Schingo; Tamara Caldaro; Francesca Laureti; Domenica Elia; Antonella Diamanti
Journal:  Eur J Pediatr Surg       Date:  2017-07-18       Impact factor: 2.191

2.  Oral insulin stimulates intestinal epithelial cell turnover following massive small bowel resection in a rat and a cell culture model.

Authors:  Shani Ben Lulu; Arnold G Coran; Naim Shehadeh; Raanan Shamir; Jorge G Mogilner; Igor Sukhotnik
Journal:  Pediatr Surg Int       Date:  2012-02       Impact factor: 1.827

3.  Reducing parenteral requirement in children with short bowel syndrome: impact of an amino acid-based complete infant formula.

Authors:  J Bines; D Francis; D Hill
Journal:  J Pediatr Gastroenterol Nutr       Date:  1998-02       Impact factor: 2.839

Review 4.  Insulin-like growth factor 1: common mediator of multiple enterotrophic hormones and growth factors.

Authors:  Sarah F Bortvedt; P Kay Lund
Journal:  Curr Opin Gastroenterol       Date:  2012-03       Impact factor: 3.287

5.  Outcomes from a 12-Week, Open-Label, Multicenter Clinical Trial of Teduglutide in Pediatric Short Bowel Syndrome.

Authors:  Beth A Carter; Valeria C Cohran; Conrad R Cole; Mark R Corkins; Reed A Dimmitt; Christopher Duggan; Susan Hill; Simon Horslen; Joel D Lim; David F Mercer; Russell J Merritt; Peter F Nichol; Luther Sigurdsson; Daniel H Teitelbaum; John Thompson; Charles Vanderpool; Juliana F Vaughan; Benjamin Li; Nader N Youssef; Robert S Venick; Samuel A Kocoshis
Journal:  J Pediatr       Date:  2016-11-15       Impact factor: 4.406

Review 6.  Glucagon-like Peptide-2 and the Regulation of Intestinal Growth and Function.

Authors:  Patricia L Brubaker
Journal:  Compr Physiol       Date:  2018-06-18       Impact factor: 9.090

7.  D-lactic acidosis in humans: systematic literature review.

Authors:  Davide G A M Bianchetti; Giacomo S Amelio; Sebastiano A G Lava; Mario G Bianchetti; Giacomo D Simonetti; Carlo Agostoni; Emilio F Fossali; Gregorio P Milani
Journal:  Pediatr Nephrol       Date:  2017-12-07       Impact factor: 3.714

8.  Markers of enteral adaptation in pediatric short bowel syndrome.

Authors:  Masahiro Chiba; Yutaka Sanada; Akira Toki
Journal:  Pediatr Int       Date:  2017-07-14       Impact factor: 1.524

9.  Intestinal Microbial and Metabolic Alterations Following Successful Fecal Microbiota Transplant for D-Lactic Acidosis.

Authors:  Emily C Bulik-Sullivan; Sayanty Roy; Ryan J Elliott; Zain Kassam; Steven N Lichtman; Ian M Carroll; Ajay S Gulati
Journal:  J Pediatr Gastroenterol Nutr       Date:  2018-10       Impact factor: 2.839

10.  GLP-1 and GLP-2 act in concert to inhibit fasted, but not fed, small bowel motility in the rat.

Authors:  Ayhan Bozkurt; Erik Näslund; Jens Juul Holst; Per M Hellström
Journal:  Regul Pept       Date:  2002-07-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.